Legend (top right):
- Group 3
- Group 9
- Group 10
- Group 11
- Total cases

$p < 0.001$

Y-axis: Surviving

X-axis: Follow up time (yrs)

LEGENDS FOR SUPPLEMENTAL TABLES AND FIGURES FOR:

Overexpression of Phospho-eIF4E Is Associated with Survival via AKT Pathway in Non-Small Cell Lung Cancer.

Akihiko Yoshizawa[1,2] Junya Fukuoka,[3] Shigeki Shimizu,[1,4] Konstantin Shilo,[5] Teri J. Franks,[5] Stephen M. Hewitt,[6] Takeshi Fujii,[7] and Carlos Cordon-Cardo[8], Jin Jen,[9] and William D. Travis[1]

1 Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, United States;
2 Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan;
3 Laboratory of Pathology, Toyama University Hospital, Toyama, Japan;
4 Department of Clinical Pathology (Pathology II) Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;
5 Department of Pulmonary & Mediastinal Pathology, AFIP, Washington, DC, United States;
6 Laboratory of Pathology, NCI, NIH, Bethesda, MD, United States;
7 Department of Pathology, Toranomon Hospital, Tokyo, Japan;
8 Department of Pathology, Columbia University, New York, NY, United States;
9 Department of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, United States;

Corresponding author:
William D. Travis, M.D.
Dept of Pathology
Memorial Sloan Kettering Cancer Center
1275 York Ave
New York, NY 10065, United States
Tel: 212-639-3325; Fax: 212-717-3576
travisw@mskcc.org

Supplemental Table 1:Clinical characteristics of all NSCLC patients in this study

Supplemental Table 2: Protein expressions and clinical variables

Abbrev. : *: Fisher's exact test (the others were judged by Chi-square test)

**: "Wel", "Mod", "Por" in Tumor Grade show well differentiated,

moderately differentiated, and poorly differentiated, respectively.

Supplemental Table 3: Relationship of expression of six phosphoproteins.

Supplemental Table4: Survival of Groups clustered by protein expression

Supplemental Figure 1: Kaplan Meier curve for Cluster Groups 3, 9, 10 and 11 showing

significant survival differences.

Variable	No. of patients	Category		Available No. for survival analysis	Median survival (yrs)	log rank
Sex	255	Male		188	2.9	0.018
		Female		67	4.3	
Age	247	60 and younger		78	3.1	0.528
64.5 +/- 9.1 (36-86)		61 and older		169	3.5	
Histology	252	ADC		131	3.3	0.556
		SqCC		121	3.8	
Grade	168	Well		23	3.2	0.266
		Moderate		69	2.7	
		Poorly		76	2.9	
Tumor size	171	30mm and smaller		99	3.8	0.112
3.3cm+/-2.4 (0.5-17.0)		31mm and larger		72	3.3	
Stage	212	I		136	4.3	0.025
		II		36	3.9	
		III		31	1.6	
		IV		9	1.2	
Vital status	254	Alive		62		<0.001
		Dead:	Tumor related	49	1.7	
			Other cause	20	1.8	
			Unknown	123	2.8	

antibody		Sex: male	female	p value	Age: =<60	>60	p value	Tumor Grade**: Wel	Mod	Por	p value	Tumor Size: =<3cm	>3cm	p value	Stage: I,II	III,IV	p value
p-AKT	posi	140	44	0.22	56	131	0.114	19	53	56	0.787	90	71	0.451	119	31	0.589
	nega	26	13		19	26		5	10	14		22	13		30	6	
PTEN	posi	153	57	0.098*	73	145	0.587*	20	62	66	0.160*	106	77	0.407	136	36	0.964*
	nega	13	1		4	11		3	3	2		6	7		11	3	
p-mTOR	posi	83	26	0.534	41	72	0.162	13	25	31	0.273	56	36	0.357	70	23	0.122
	nega	90	34		36	93		10	42	41		61	51		85	16	
p-TSC2	posi	13	4	0.876*	8	9	0.183	2	9	3	0.158*	81	5	0.331	15	2	0.353*
	nega	160	54		70	153		21	58	68		104	11		137	37	
p-S6	posi	54	12	0.101	18	47	0.332	7	17	23	0.723	38	20	0.147	48	8	0.244
	nega	120	48		61	117		17	50	50		80	67		109	30	
p-eIF4E	posi	69	22	0.794	34	59	0.273	8	23	35	0.166	42	38	0.24	53	20	0.046
	nega	107	37		45	106		17	43	37		76	49		103	19	
p-Erk1/2	posi	37	7	0.105	13	30	0.801	6	14	10	0.314	30	10	0.01	31	6	0.599
	nega	141	54		66	139		17	54	64		89	80		128	32	

*: Fisher's exact test (the others were judged by Chi-square test)

**: "Wel", "Mod", "Por" in Tumor Grade show well differentiated, moderately differentiated, and poorly differentiated, respectively.

antibody	antibody	Spearman coefficients (r)	p value
p-eIF4E	p-AKT	0.375	<0.001
	p-Erk1/2	0.053	0.382
	p-TSC2	0.208	<0.001
	p-mTOR	0.121	0.044
	p-S6	0.366	<0.001
p-S6	p-AKT	0.248	<0.001
	p-Erk1/2	0.36	<0.001
	p-TSC2	0.13	0.033
	p-mTOR	0.156	0.01
p-mTOR	p-AKT	0.041	0.513
	p-Erk1/2	0.149	0.014
	p-TSC2	0.107	0.078
p-TSC2	p-AKT	0.202	0.001
	p-Erk1/2	0.252	<0.001
p-AKT	p-Erk1/2	0.101	0.101

	Case(n)	MST*(yrs)	5-year survival rate (%)	Log-rank p vaule (Group X vs. the others)
Cluster Group	254	3.4	38.1	
Group 1	7	3.5	40	0.332
Group 2	15	5.3	55.6	0.32
Group 3	16	9.4	75	0.019
Group 4	8	2.6	33.3	0.407
Group 5	28	5.8	51	0.069
Group 6	38	2.7	28	0.328
Group 7	20	3.6	42.2	0.315
Group 8	13	3.5	27.3	0.554
Group 9	12	0.7	12	0.006
Group 10	13	2.2	0	0.01
Group 11	13	1.2	25	0.04
Group 12	12	2	36.4	0.614
Group 13	32	2.7	30.3	0.558
Group 14	6	NA**	50	0.664
Group 15	21	2.4	38.9	0.667

*: MST(yrs):median survival time(years)

**: NA: not available